发布求助
文献互助 智能选刊 最新文献

Trends in cancer最新文献

筛选
英文 中文
Repurposing glucose-lowering drugs for cancer therapy. 将降糖药物用于癌症治疗。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-05-15 DOI: 10.1016/j.trecan.2025.04.010
Michaela Luconi, Giulia Cantini, Clara Crescioli
{"title":"Repurposing glucose-lowering drugs for cancer therapy.","authors":"Michaela Luconi, Giulia Cantini, Clara Crescioli","doi":"10.1016/j.trecan.2025.04.010","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.04.010","url":null,"abstract":"<p><p>The acknowledged relationship between metabolism and cancer retains important potential as a novel target in therapy. Reallocating glucose-lowering drugs (GLDs) in cancer treatment offers valuable perspectives for the ability of these molecules to regulate metabolism at cellular and systemic level. This comprehensive review addresses the therapeutic potential of the main antidiabetic classes of glucose-lowering drugs with emerging anticancer effects, such as metformin, rosiglitazone, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium/glucose cotransporter-2 inhibitors. The multifaceted actions of these drugs are explored, from in vitro evidence to clinical evidence as monotherapy or as a sparing agent with chemotherapy and immunotherapy. For each molecule, unconventional mechanisms, benefits, and limitations are dissected and possible concerns addressed, supporting evidence for the potential use of the drug in cancer.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting GPX4 palmitoylation to boost antitumor immunity. 靶向GPX4棕榈酰化增强抗肿瘤免疫。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-05-14 DOI: 10.1016/j.trecan.2025.05.001
Daehee Hwang, Whitney S Henry
{"title":"Targeting GPX4 palmitoylation to boost antitumor immunity.","authors":"Daehee Hwang, Whitney S Henry","doi":"10.1016/j.trecan.2025.05.001","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.05.001","url":null,"abstract":"<p><p>Despite significant milestones in cancer immunotherapy, tumor cells often escape immune surveillance. Zhou et al. revealed that the pivotal ferroptosis suppressor glutathione peroxidase 4 (GPX4) can undergo palmitoylation by zDHHC8, enhancing ferroptosis resistance. This study highlights the potential of targeting GPX4 palmitoylation to enhance cytotoxic T cell-mediated ferroptosis of tumor cells.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting vulnerabilities of aneuploid cells for cancer therapy. 靶向非整倍体细胞的脆弱性用于癌症治疗。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-05-13 DOI: 10.1016/j.trecan.2025.04.005
Johanna Zerbib, Amit Bloomberg, Uri Ben-David
{"title":"Targeting vulnerabilities of aneuploid cells for cancer therapy.","authors":"Johanna Zerbib, Amit Bloomberg, Uri Ben-David","doi":"10.1016/j.trecan.2025.04.005","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.04.005","url":null,"abstract":"<p><p>Aneuploidy is a common feature of cancer that drives tumor evolution, but it also creates cellular vulnerabilities that might be exploited therapeutically. Recent advances in genomic technologies and experimental models have uncovered diverse cellular consequences of aneuploidy, revealing dependencies on mitotic regulation, DNA replication and repair, proteostasis, metabolism, and immune interactions. Harnessing aneuploidy for precision oncology requires the combination of genomic, functional, and clinical studies that will enable translation of our improved understanding of aneuploidy to targeted therapies. In this review we discuss approaches to targeting both highly aneuploid cells and cells with specific common aneuploidies, summarize the biological underpinning of these aneuploidy-induced vulnerabilities, and explore their therapeutic implications.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor-draining lymph nodes - friend or foe during immune checkpoint therapy? 肿瘤引流淋巴结——免疫检查点治疗的朋友还是敌人？
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-05-09 DOI: 10.1016/j.trecan.2025.04.008
Janusz von Renesse, Mei-Chun Lin, Ping-Chih Ho
{"title":"Tumor-draining lymph nodes - friend or foe during immune checkpoint therapy?","authors":"Janusz von Renesse, Mei-Chun Lin, Ping-Chih Ho","doi":"10.1016/j.trecan.2025.04.008","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.04.008","url":null,"abstract":"<p><p>The pivotal role of tumor-draining lymph nodes (TDLNs) in supporting antitumor immunity and serving as sites for cancer metastasis presents a clinical challenge: eliminate tumors while preserving antitumor immune responses. In this article, we explore the initiation of tumor-specific immune responses within lymph nodes (LNs), the immunocompromised microenvironment induced by tumors within LNs, and the crucial involvement of TDLNs in immunotherapy. Additionally, we examine the clinical prospects of modifying surgical procedures or therapy sequences to enhance the efficacy of cancer treatment.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mixing it up: boosting responses with immunotherapy combinations. 混合：用免疫疗法组合来增强反应。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-05-06 DOI: 10.1016/j.trecan.2025.04.013
Hiroki Komatsuda, Edward S Sim, Ravindra Uppaluri
{"title":"Mixing it up: boosting responses with immunotherapy combinations.","authors":"Hiroki Komatsuda, Edward S Sim, Ravindra Uppaluri","doi":"10.1016/j.trecan.2025.04.013","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.04.013","url":null,"abstract":"<p><p>Whether combination neoadjuvant immunotherapy can enhance response in patients with head and neck cancer remains unclear. Recently, Li et al. demonstrated improved responses with neoadjuvant anti-PD-1+CTLA-4 or anti-PD-1+LAG-3 compared with anti-PD-1 monotherapy. These combination strategies act via different mechanisms with distinct biomarkers of response, highlighting the potential for personalized neoadjuvant immunotherapy approaches.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144028909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epigenetic mechanisms in melanoma development and progression. 黑色素瘤发生和进展的表观遗传机制。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-05-05 DOI: 10.1016/j.trecan.2025.04.007
Hyunjeong Joo, Ximena Diaz Olea, Aojia Zhuang, Bin Zheng, Hyungsoo Kim, Ze'ev A Ronai
{"title":"Epigenetic mechanisms in melanoma development and progression.","authors":"Hyunjeong Joo, Ximena Diaz Olea, Aojia Zhuang, Bin Zheng, Hyungsoo Kim, Ze'ev A Ronai","doi":"10.1016/j.trecan.2025.04.007","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.04.007","url":null,"abstract":"<p><p>Knowledge of cancer development and progression gained over the last few decades has enabled mapping of genetic and epigenetic changes unique to different phases of tumor evolution. Here we focus on epigenetic changes that drive melanoma development and progression. We highlight the importance of epigenetic mechanisms which encompass crosstalk with melanoma microenvironment that affect metastasis and therapy resistance. This review summarizes recent advances and describes potential strategies to leverage this knowledge to devise new therapies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leveraging space innovations for cancer breakthroughs on Earth. 利用太空创新来突破地球上的癌症。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-05-01 Epub Date: 2025-03-12 DOI: 10.1016/j.trecan.2025.02.003
Hossein Akbarialiabad, Parnian Jamshidi, Zahra Aminzade, Narges Azizi, Seyed Reza Taha, Najmeh Sadeghian, Lydia Johnson Kolaparambil Varghese, Mohsen Farjoud Kouhanjani, Nafise Niknam, Dora Babocs, Fatima El-Assaad, Thais Russomano, Dedee F Murrell, Shahram Paydar, Christopher G Bunick, Rowena Christiansen, M Mark Melin
{"title":"Leveraging space innovations for cancer breakthroughs on Earth.","authors":"Hossein Akbarialiabad, Parnian Jamshidi, Zahra Aminzade, Narges Azizi, Seyed Reza Taha, Najmeh Sadeghian, Lydia Johnson Kolaparambil Varghese, Mohsen Farjoud Kouhanjani, Nafise Niknam, Dora Babocs, Fatima El-Assaad, Thais Russomano, Dedee F Murrell, Shahram Paydar, Christopher G Bunick, Rowena Christiansen, M Mark Melin","doi":"10.1016/j.trecan.2025.02.003","DOIUrl":"10.1016/j.trecan.2025.02.003","url":null,"abstract":"<p><p>Space science is reshaping oncology by providing novel insights into cancer biology, diagnostics, and therapeutics. The unique space environment - characterized by microgravity and cosmic radiation - induces profound alterations in cancer cell behavior, immune responses, and tumor microenvironment (TME) interactions. These conditions offer a platform for studying cancer progression, enhancing drug discovery, and refining treatment strategies. This opinion article explores microgravity-induced changes in tumor biology, space-driven advancements in imaging and radiation research, and extraterrestrial contributions to cancer therapeutics. By leveraging these innovations, space research holds transformative potential for improving cancer diagnostics and treatment on Earth.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"433-440"},"PeriodicalIF":14.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The enigma of maladaptation in gastric pathophysiology. 胃病理生理中的不适应之谜。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-05-01 Epub Date: 2025-02-20 DOI: 10.1016/j.trecan.2025.01.014
Gunter Maubach, Arun K Kanthasamy, Sandro Gogia, Michael Naumann
{"title":"The enigma of maladaptation in gastric pathophysiology.","authors":"Gunter Maubach, Arun K Kanthasamy, Sandro Gogia, Michael Naumann","doi":"10.1016/j.trecan.2025.01.014","DOIUrl":"10.1016/j.trecan.2025.01.014","url":null,"abstract":"<p><p>Despite a decline in global incidence, gastric cancer (GC) remains a major health concern. The development of GC is a sequential, multistage maladaptive process involving numerous different factors. Understanding the complexity of GC development is crucial for early detection, effective treatment, and, ultimately, prevention. In this respect, identifying the impact of risk factors contributing to the emergence or progression of GC, such as Helicobacter pylori infection, host and bacterial genetics, alcohol consumption, smoking, and preserved foods, will aid in combatting this disease. In this review, we focus on recent developments in understanding the role of the microbiome, dysfunctional molecular pathways, and immune evasion in gastric pathophysiology. We also highlight challenges and advances in treatment of GC.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"448-461"},"PeriodicalIF":14.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting PI3Kγ in cancer. 靶向癌症中的PI3Kγ
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-05-01 Epub Date: 2025-02-12 DOI: 10.1016/j.trecan.2025.01.008
Giuliana P Mognol, Anghesom Ghebremedhin, Judith A Varner
{"title":"Targeting PI3Kγ in cancer.","authors":"Giuliana P Mognol, Anghesom Ghebremedhin, Judith A Varner","doi":"10.1016/j.trecan.2025.01.008","DOIUrl":"10.1016/j.trecan.2025.01.008","url":null,"abstract":"<p><p>The phosphoinositide 3-kinases (PI3Ks) have been the focus of a significant body of cancer research since their discovery nearly 40 years ago. These lipid kinases are now known to play central roles in cancer cell proliferation, survival, migration, metabolism, and immunity and serve as the target of numerous investigational and approved therapeutics. One of these kinases, the unique class IB PI3Kγ, which is highly expressed in myeloid lineage cells and myeloid leukemias, plays prominent roles in tumor immune suppression. Inhibition of this kinase has promoted improved antitumor immune responses in recent solid tumor preclinical studies and clinical trials. New studies also identify this kinase as a driver of acute myeloid leukemia self-renewal and as a new target for the treatment of aggressive leukemias.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"462-474"},"PeriodicalIF":14.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inciting commensal human papillomavirus immunity to combat cancer. 激发人类乳头瘤病毒共生免疫以对抗癌症。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-05-01 DOI: 10.1016/j.trecan.2025.04.006
Natalie E Fulton, Thomas D Horn, Shadmehr Demerhi
{"title":"Inciting commensal human papillomavirus immunity to combat cancer.","authors":"Natalie E Fulton, Thomas D Horn, Shadmehr Demerhi","doi":"10.1016/j.trecan.2025.04.006","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.04.006","url":null,"abstract":"<p><p>The incidence of squamous cell carcinoma (SCC) is rising, especially in immunosuppressed individuals, highlighting the need for new prevention strategies. Commensal human papillomaviruses (cHPVs) are associated with cutaneous SCC (cSCC) in immunosuppressed patients. Because of the intricate interactions between T cell immunity and cHPVs in virus-colonized tissues, we propose that enhancing T cell immunity against cHPVs through vaccination could suppress SCC.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信